---
created: '2026-02-08T19:45:44.646055Z'
description: This systematic review and meta-analysis of 46 randomized controlled
  trials (n=4,158 participants) evaluated the efficacy and safety of berberine for
  type 2 diabetes. Berberine significantly reduced fasting blood glucose, HbA1c, and
  improved lipid profiles through AMPK activation. The analysis demonstrated berberine's
  potential as an adjunct therapy for metabolic disorders.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/research/efficacy-and-safety-of-berberine-for-type-2-diabetes-a-systematic-review-and-meta-analysis/
slug: efficacy-and-safety-of-berberine-for-type-2-diabetes-a-systematic-review-and-meta-analysis
tags:
- research
- berberine
- AMPK
- type 2 diabetes
- meta-analysis
- glucose metabolism
- systematic review
title: 'Efficacy and safety of berberine for type 2 diabetes: A systematic review
  and meta-analysis'
type: research
updated: '2026-02-08T19:45:44.646055Z'
---

# Efficacy and safety of berberine for type 2 diabetes: A systematic review and meta-analysis 
## Study Information
**Authors**: Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J**Journal**: Frontiers in Pharmacology
**Publication Date**: 2020-09-01
**Type**: Meta-Analysis
**Study Design**: Systematic Review and Meta-Analysis**Citations**: 285**DOI**: [10.3389/fphar.2020.01260](https://doi.org/10.3389/fphar.2020.01260)**PMID**: [32891636](https://pubmed.ncbi.nlm.nih.gov/32891636/)**PMC**: [PMC7453919](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453919/)**Semantic Scholar**: [View](https://www.semanticscholar.org/paper/PMID:32891636)
## Abstract
This systematic review and meta-analysis of 46 randomized controlled trials (n=4,158 participants) evaluated the efficacy and safety of berberine for type 2 diabetes. Berberine significantly reduced fasting blood glucose, HbA1c, and improved lipid profiles through AMPK activation. The analysis demonstrated berberine's potential as an adjunct therapy for metabolic disorders. 
## Keywords
berberine, AMPK, type 2 diabetes, meta-analysis, glycemic control, lipid metabolism, insulin sensitivity
<!-- NEO4J_CONTENT_START -->
## Relationships
No relationships found.
<!-- NEO4J_CONTENT_END -->
## Methodology
```yaml
'{"databases_searched": ["PubMed", "Cochrane Library", "EMBASE", "CNKI", "Wanfang"],
  "design": "Systematic review and meta-analysis", "inclusion_criteria": "RCTs comparing
  berberine with placebo or standard care in T2DM", "quality_assessment": "Cochrane
  Risk of Bias tool", "statistical_method": "Random-effects model (DerSimonian-Laird)"}'
```

### Study Design
- **Sample Size**: n=4158- **Duration**: 4-24 weeks (across included studies)#### Population Characteristics
```yaml
'{"age_range": "Adults with type 2 diabetes", "health_status": "Type 2 diabetes mellitus",
  "participants": 4158, "total_studies": 46}'
```

## Results
### Key Findings
```yaml
'{"primary": [{"heterogeneity": "I2 = 89%", "name": "Fasting blood glucose", "p_value":
  "<0.00001", "result": "Significant reduction (MD: -0.87 mmol/L)"}, {"name": "HbA1c",
  "p_value": "<0.00001", "result": "Significant reduction (MD: -0.72%)"}], "secondary":
  [{"name": "Total cholesterol", "result": "Significant reduction (MD: -0.58 mmol/L)"},
  {"name": "LDL cholesterol", "result": "Significant reduction (MD: -0.38 mmol/L)"},
  {"name": "Triglycerides", "result": "Significant reduction (MD: -0.41 mmol/L)"},
  {"name": "Adverse events", "result": "Mild GI symptoms, similar to control"}]}'
```

### Statistical Analysis
#### Statistical Significance
```yaml
'{"fbg": "p < 0.00001, MD: -0.87 mmol/L, 95% CI: -1.09 to -0.64", "hba1c": "p < 0.00001,
  MD: -0.72%, 95% CI: -0.91 to -0.54"}'
```
#### Effect Sizes
```yaml
'{"fbg_reduction": "0.87 mmol/L (15.7 mg/dL)", "hba1c_reduction": "0.72%", "nnt":
  "Approximately 4-5 for clinically meaningful improvement"}'
```

## Limitations
- High heterogeneity among studies (I2 = 89%)
- Variable berberine dosages (0.5-1.5 g/day)
- Mostly Chinese study populations
- Short to medium duration studies
- Potential publication bias

## Research Integrity
### Funding Sources
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
### Conflicts of Interest
- None declared

## Replication Status
Consistent with previous meta-analyses; findings support earlier systematic reviews

## References
- Yin J et al. Metabolism. 2008;57(5):712-717. PMID: 18442638
- Kong W et al. Nat Med. 2004;10(12):1344-1351. PMID: 15531889
- Zhang Y et al. J Clin Endocrinol Metab. 2008;93(7):2559-2565. PMID: 18397984

## Source Data
- **Source System:** PubMed - **Last Modified in Source:** 2026-01-25T21:22:09.460007+00:00